{"denoms":[{"counts":[{"groupId":"BG000","value":"20"}],"units":"Participants"}],"groups":[{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.\n\npaclitaxel: Given IV dosage 135 mg/m2/dose\n\ncarboplatin: Given IV dosage in mg/m2 = Target AUC (mg•min/mL) x \\[(0.93 x GFR mL/min/m2) + 15\\]= 6.5 x \\[(0.93 x GFR mL/min/m2) + 15\\]. (BSA = body surface area in square meters). GFR is reported in institutions as \"uncorrected\" or \"raw\" (not normalized to BSA) or \"corrected.\" This number needs to be converted to GFR in mL/min/m2.\n\nifosfamide: Given IV dosage 1800 mg/m2/dose\n\nfilgrastim: Given IV or subcutaneously dosage 1,080mg/m2/day divided to three equal doses of 360mg/m2\n\nlaboratory biomarker analysis: Optional correlative studies","id":"BG000","title":"Treatment (Chemotherapy, Biological Therapy)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"18","value":"13.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Puerto Rico"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}